The AF-FLOW Registry is a prospective, multi-center global post-market registry that will obtain clinical data in order to characterize the performance of the Ablamap® Software for its intended use in a real-world setting. Specifically, we will evaluate the ability of the Ablamap® Software to identify AF sources and guide ablation therapy in patients with atrial fibrillation. This registry will enroll up to 100 subjects. Subjects that present with atrial fibrillation and meet inclusion/exclusion criteria will be eligible for enrollment.
This post-market global registry will evaluate the ability of the Ablamap® Software to identify atrial fibrillation sources and guide ablation therapy in patients with atrial fibrillation.